BioCentury | Nov 21, 2020
Product Development

Nov. 20 Quick Takes: uniQure hemophilia therapy hits pivotal endpoint; plus data from Gilead in HIV, Aivita  in GBM and a setback for Poxel

uniQure hemophilia therapy hits co-primary Phase III endpointuniQure N.V. (NASDAQ:QURE) said gene therapy etranacogene dezaparvovec met one primary endpoint of the Phase III HOPE-B trial to treat hemophilia B. The adeno-associated viral serotype 5 (AAV5)...
BioCentury | Nov 12, 2020
Product Development

Russian vaccine data add to expectations for COVID-19 vaccine efficacy set by BioNTech, Pfizer; Moderna readout coming

The first interim Phase III readout for Sputnik V suggests the Russian COVID-19 vaccine and BNT162b2 from BioNTech and Pfizer have similar efficacies as an interim analysis that will reveal whether Moderna...
BioCentury | Sep 1, 2020
Product Development

Disease setting shields Vir, GSK trial of COVID-19 mAb from plasma EUA

The outpatient setting of the first clinical trial of Vir and GSK’s lead antiviral COVID-19 mAb buffers the study from being affected by FDA’s emergency use authorization for convalescent plasma. The partners also differentiated their...
BioCentury | Jun 6, 2020
Product Development

AAV COVID-19 vaccine aims for the sweet spot between antibody and T cell immunity

The academic team behind the only AAV vaccine candidate for COVID-19 thinks its vector can get the best of both worlds and induce stronger antibody responses than adenoviral vaccines, while still activating T cells. Moreover,...
BioCentury | May 16, 2020
Product Development

A guide to COVID-19 preclinical vaccine modalities

As the number of vaccines in development for COVID-19 climbs past 110, more modalities are starting to be represented in the clinic. As of last week, the COVID-19 vaccine modalities in the clinic were inactivated...
BioCentury | Apr 17, 2020
Product Development

Vir’s dose response, safety data spur combo studies of Alnylam-partnered HBV therapy

With an eye towards a functional cure for chronic HBV, Vir plans to begin testing its siRNA therapy next half in combination with immune boosters. Phase I/II data unveiled Wednesday showed that VIR-2218 alone led...
BioCentury | Mar 27, 2020
Product Development

COVID-19 roundup: biopharmas scramble to reassess clinical timelines; plus CEPI-Dynavax, and emergency approvals for Vero, Fosun

More than a dozen biopharmas Thursday announced delays or disruptions to clinical programs and regulatory timelines as companies begin to turn their attention to managing their trials through the COVID-19 crisis. The setbacks came as...
BioCentury | Mar 13, 2020

Flagship’s Repertoire combines Cogen, Torque to pick antigens for immunotherapies

By combining TCR-antigen matching company Cogen with T cell therapy play Torque, Flagship Pioneering’s Repertoire Immune Medicines Inc. aims to boost the latter’s ongoing oncology programs while demonstrating clinical proof of concept for the former’s...
BioCentury | Oct 11, 2019
Financial News

Vir’s aftermarket weakness adds to skittishness for IPO queue

The tepid performances of two high-profile IPOs late in the week added to a widening body of evidence that investors’ demand for new biotech listings has begun to weaken, despite a long queue of companies...
BioCentury | Sep 4, 2019
Financial News

Vir plots IPO as more programs near clinic

Although more than half of the $630.7 million in equity funding that Vir Biotechnology has raised remains unspent, the immunology and infectious disease company -- led by former Biogen and Exelixis CEO George Scangos --...
Items per page:
1 - 10 of 356